Health Care [ 6/12 ] | Pharmaceuticals [ 30/74 ]
NASDAQ | Common Stock
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -0.03 Increased by +66.67% | -0.84 Increased by +96.43% |
| Nov 7, 24 | 0.00 Increased by +102.88% | -0.05 Increased by +104.60% |
| Aug 8, 24 | -0.05 Decreased by -350.00% | -0.08 Increased by +37.50% |
| May 14, 24 | -0.12 Increased by +29.41% | -0.11 Decreased by -9.09% |
| Mar 7, 24 | -0.09 Increased by +47.06% | -0.09 |
| Nov 9, 23 | -0.08 Increased by +55.56% | -0.09 Increased by +11.11% |
| Aug 10, 23 | 0.02 Increased by +108.70% | -0.11 Increased by +118.18% |
| May 11, 23 | -0.17 Increased by +45.16% | -0.14 Decreased by -21.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 22.42 M Increased by +12.86% | -360.00 K Increased by +96.39% | Decreased by -1.61% Increased by +96.80% |
| Sep 30, 24 | 20.44 M Increased by +3.10% | 467.00 K Increased by +105.02% | Increased by +2.29% Increased by +104.87% |
| Jun 30, 24 | 20.49 M Increased by +5.33% | -7.58 M Decreased by -388.69% | Decreased by -37.00% Decreased by -374.09% |
| Mar 31, 24 | 14.88 M Increased by +25.61% | -14.07 M Increased by +24.59% | Decreased by -94.54% Increased by +39.97% |
| Dec 31, 23 | 19.86 M Decreased by -4.75% | -9.97 M Increased by +42.49% | Decreased by -50.17% Increased by +39.62% |
| Sep 30, 23 | 19.82 M Decreased by -1.27% | -9.29 M Increased by +37.83% | Decreased by -46.88% Increased by +37.03% |
| Jun 30, 23 | 19.45 M Decreased by -5.48% | 2.63 M Increased by +113.54% | Increased by +13.50% Increased by +114.32% |
| Mar 31, 23 | 11.85 M Decreased by -19.74% | -18.65 M Increased by +26.36% | Decreased by -157.47% Increased by +8.25% |